$779 Million is the total value of VR Adviser, LLC's 26 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 58.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TIL | INSTIL BIO INC | $122,713,000 | -7.5% | 6,865,076 | 0.0% | 15.76% | -2.0% | |
| ACRS | ACLARIS THERAPEUTICS INC | $82,151,000 | +2.5% | 4,563,962 | 0.0% | 10.55% | +8.5% | |
| CLDX | Sell | CELLDEX THERAPEUTICS INC | $59,290,000 | +42.9% | 1,098,174 | -11.5% | 7.62% | +51.3% |
| New | AADI BIOSCIENCE INC | $44,919,000 | – | 1,529,402 | +100.0% | 5.77% | – | |
| VTGN | VISTAGEN THERAPEUTICS INC | $43,970,000 | -13.0% | 16,047,286 | 0.0% | 5.65% | -7.9% | |
| ALT | Buy | ALTIMMUNE INC | $42,978,000 | +24.7% | 3,800,000 | +8.6% | 5.52% | +32.0% |
| OLMA | OLEMA PHARMACEUTICALS INC | $42,337,000 | -1.5% | 1,536,193 | 0.0% | 5.44% | +4.3% | |
| TVTX | New | TRAVERE THERAPEUTICS INC | $42,011,000 | – | 1,732,410 | +100.0% | 5.40% | – |
| RLMD | RELMADA THERAPEUTICS INC | $36,372,000 | -18.1% | 1,387,720 | 0.0% | 4.67% | -13.3% | |
| GHRS | Buy | GH RESEARCH PLCord sh | $36,229,000 | +30.7% | 1,642,296 | +28.7% | 4.65% | +38.4% |
| KNTE | KINNATE BIOPHARMA INC | $33,909,000 | -1.1% | 1,473,014 | 0.0% | 4.36% | +4.7% | |
| MARINUS PHARMACEUTICALS INC | $30,064,000 | -36.6% | 2,641,809 | 0.0% | 3.86% | -32.8% | ||
| GRPH | GRAPHITE BIO INC | $26,431,000 | -46.7% | 1,612,617 | 0.0% | 3.40% | -43.5% | |
| CNTA | CENTESSA PHARMACEUTICALS PLCspons adr | $18,825,000 | -24.8% | 1,127,272 | 0.0% | 2.42% | -20.4% | |
| New | NUVALENT INC | $18,129,000 | – | 803,951 | +100.0% | 2.33% | – | |
| CRVS | New | CORVUS PHARMACEUTICALS INC | $16,589,000 | – | 3,427,461 | +100.0% | 2.13% | – |
| CGEM | Sell | CULLINAN ONCOLOGY INC | $15,936,000 | -36.6% | 706,050 | -27.7% | 2.05% | -32.9% |
| LIFE | New | ATYR PHARMA INC | $14,210,000 | – | 1,565,000 | +100.0% | 1.82% | – |
| ATHA | Sell | ATHIRA PHARMA INC | $11,220,000 | -26.2% | 1,196,196 | -19.4% | 1.44% | -21.9% |
| PHVS | Sell | PHARVARIS NV | $9,803,000 | -41.7% | 552,882 | -38.8% | 1.26% | -38.3% |
| COGT | COGENT BIOSCIENCES INC | $9,157,000 | +3.7% | 1,088,817 | 0.0% | 1.18% | +9.8% | |
| CVRX | Sell | CVRX INC | $8,822,000 | -50.3% | 533,370 | -15.8% | 1.13% | -47.3% |
| AKYA | AKOYA BIOSCIENCES INC | $5,584,000 | -27.8% | 400,000 | 0.0% | 0.72% | -23.6% | |
| New | ASTRIA THERAPEUTICS INC | $4,765,000 | – | 538,999 | +100.0% | 0.61% | – | |
| TCDA | New | TRICIDA INC | $1,813,000 | – | 390,707 | +100.0% | 0.23% | – |
| VRDN | VIRIDIAN THERAPEUTICS INC | $321,000 | -10.1% | 19,495 | 0.0% | 0.04% | -4.7% | |
| ACET | Exit | ADICET BIO INC | $0 | – | -183,702 | -100.0% | -0.23% | – |
| Exit | CATABASIS PHARMACEUTICALS INC | $0 | – | -3,234,000 | -100.0% | -0.83% | – | |
| HARP | Exit | HARPOON THERAPEUTICS INC | $0 | – | -512,005 | -100.0% | -0.86% | – |
| ALGS | Exit | ALIGOS THERAPEUTICS INC | $0 | – | -408,377 | -100.0% | -1.01% | – |
| KROS | Exit | KEROS THERAPEUTICS INC | $0 | – | -272,306 | -100.0% | -1.40% | – |
| KURA | Exit | KURA ONCOLOGY INC | $0 | – | -575,000 | -100.0% | -1.45% | – |
| RAPT | Exit | RAPT THERAPEUTICS INC | $0 | – | -391,000 | -100.0% | -1.51% | – |
| EPIX | Exit | ESSA PHARMA INC | $0 | – | -625,754 | -100.0% | -2.17% | – |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -2,001,686 | -100.0% | -2.36% | – | |
| PRVB | Exit | PROVENTION BIO INC | $0 | – | -2,902,744 | -100.0% | -2.97% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 12 | Q3 2023 | 12.7% |
| VIRIDIAN THERAPEUTICS INC | 12 | Q3 2023 | 13.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.3% |
| RELMADA THERAPEUTICS INC | 11 | Q3 2022 | 9.9% |
| GH RESEARCH PLC | 10 | Q3 2023 | 6.7% |
| ALTIMMUNE INC | 9 | Q3 2022 | 11.6% |
| MARINUS PHARMACEUTICALS INC | 9 | Q4 2022 | 5.7% |
| CELLDEX THERAPEUTICS INC | 9 | Q3 2022 | 7.6% |
| AFFIMED N V | 8 | Q3 2023 | 1.1% |
| INSTIL BIO INC | 7 | Q3 2022 | 18.7% |
View VR Adviser, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View VR Adviser, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.